Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Late Relapse After Chemotherapy and ASCT in DLBCL
Clin Lymphoma Myeloma Leuk; ePub 2016 Nov 22; Hunter, et al
People with relapsed or refractory DLBCL who experienced relapse more than 1 year after ASCT had good outcomes in a retrospective analysis involving 85 individuals.
Participants underwent ASCT between 2001 and 2010 at a single center. All patients received rituximab. Investigators looked at 27 who relapsed as part of 2 groups: those relapsing ≤1 year and >1-year after ASCT. Among the results:
- Over a median follow-up of ~6.5 years, overall survival after ASCT relapse was~ 5 years for all patients.
- Median overall and progression-free survival was less than a year in patients who relapsed ≤1 year after ASCT.
- Median overall and progression-free survival was ~6 and ~3 years, respectively, in those who relapsed >1 year after ASCT.
The authors suggested continued monitoring in these patients for potential subsequent progression.
Hunter B, Herr M, Meacham P, et al. Late relapses following high dose chemotherapy and autologous stem cell transplant in patients with diffuse large b cell lymphoma in the rituximab era. [Published online ahead of print November 22, 2016]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.bbmt.2016.11.011.